Altria Group, Inc. · NYSE:MO
Altria — Global Forum on Nicotine 2018
13 slides from Altria's conference presentation, Jun 14, 2018
Slide 1: The Harm Reduction Opportunity with Innovative Oral Tobacco-Derived Nicotine Products
The Harm Reduction Opportunity with Innovative Oral Tobacco-Derived Nicotine Products Global Forum on Nicotine June 14th 2018 Mohamadi Sarkar M. Pharm, Ph.D., FCCP Fellow, Scientific Strategy and Analysis Altria Client Services Altria Client Services l Regulatory Affairs l Global Forum on Nicotine l
Slide 2: Agenda
Agenda Current Situation VERVE® - Innovative Oral Tobacco Derived Nicotine Products ALCS Framework for Assessing Harm Reduction - Scientific Evidence Overall Conclusions Altria Client Services l Regulatory Affairs l Global Forum on Nicotine l 6/14/2018 l FINAL | 2
Slide 3: Cigarette Smoking: A Significant Public Health Problem
Cigarette Smoking: A Significant Public Health Problem Cigarette smoking Cigarette smoking Smokers’ life causes about causes an expectancy one of every estimated 480,000 is about five deaths annually deaths annually 10 years shorter in the U.S. than nonsmokers’ Source: http://www.cdc.gov/tobacco/dat
Slide 4: Harm Reduction Opportunities
Harm Reduction Opportunities ~5 MM Adult Smokeless Consumers ~40 MM Adult Cigarette Smokers ~10 MM Adult E-Vapor Consumers Note: Figures shown are U.S Adult Tobacco Consumers Source: 18+ATCT 12MM ending December 2017 Numbers may not foot due to rounding Altria Client Services l Regulatory Affairs l
Slide 5: FDA Recognizes Continuum of Risk
FDA Recognizes Continuum of Risk “We must recognize the potential for innovation to lead to less harmful products, which, under FDA’s oversight, could be part of a solution. While there’s still much research to be done on these products and the risks that they may pose, they may also present benefit
Slide 6: Over Half of U.S. Adult Smokers Are Interested in Reduced-Risk Tobacco Products
Over Half of U.S. Adult Smokers Are Interested in Reduced-Risk Tobacco Products Numbers may not foot due to rounding Source: Based on ALCS analysis of PATH Wave 1 data Sept 12, 2013 – Dec 14, 2014; Response to question – “If a tobacco product made a claim that it was less harmful to health than othe
Slide 7: Innovative Non-Combustible Product Platforms
Innovative Non-Combustible Product Platforms Oral Tobacco‐Derived Nicotine E‐Vapor Heated Tobacco Altria Client Services l Regulatory Affairs l Global Forum on Nicotine l 6/14/2018 l FINAL | 7
Slide 8: VERVE Discs Product Overview
VERVE® Discs Product Overview Innovative Oral Tobacco-Derived Nicotine Discs Flavor Varieties: Blue Mint & Green Mint VERVE® Discs contain: - USP Grade Tobacco-Derived Nicotine - Food Grade Ingredients - Biocompatible Medical Grade Polymer ~1.5mg of nicotine per Disc 16 Discs per child resis
Slide 9: VERVE Chews Product Overview
VERVE® Chews Product Overview Innovative Oral Tobacco-Derived Nicotine Chews Flavor Varieties: Blue Mint & Green Mint VERVE® Chews contain: - USP Grade Tobacco-Derived Nicotine - Food Grade Ingredients ~1.5mg of nicotine per Chew 12 Chews per child resistant package Altria Client Services l
Slide 10: ALCS Reduced Harm Evaluation Framework
ALCS Reduced Harm Evaluation Framework Constituent Individual Risk Population Harm Reduction Reduction Reduction Risks and Product Chemical Toxicology Studies in Adult Perception Benefits to Design and and Physical and Risk Human and Behavior Health of the Control Characterization Assessment Subject
Slide 11: Percent Reduction in HPHC Levels of VERVE Products Compared to Cigarettes
Percent Reduction in HPHC levels of VERVE® Products Compared to Cigarettes in Market 100.0% 80.0% 41% >99% >99% >93% >99% >99% >99% 60.0% **Arsenic levels 40.0% were higher only in VERVE® Chews products compared to levels in 20.0% Not Detectable cigarettes. These levels were lower than those found i
Slide 12: Continued Decline of CPD When Switching to VERVE Products
Continued Decline of CPD When Switching to VERVE® Products 50‐99% Reduction at Week 6 (n=202/517) 50‐99% Reduction at Week 12 (n= 76/410) No Cigarettes at Week 6 (n=120/517) No Cigarettes at Week 12 (n= 17/410) 20 18.5 20 18 16 16 14.6 Average number of CPD Average number of CPD 14 13.8 14.4 12 12 9
Slide 13: Overall Conclusions
Overall Conclusions Over half of U.S. Adult Smokers are interested in reduced-risk tobacco products We have a robust framework to develop and evaluate our oral tobacco products to demonstrate harm reduction Innovative oral tobacco-derived nicotine products present an opportunity to reduce the